Abstract
PD-L1 structural variants are recurrent in mycosis fungoides with large cell transformation.
PD-L1 structural variants in relapsed/refractory mycosis fungoides should prompt consideration of treatment with PD-1 inhibitors.
MeSH terms
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
B7-H1 Antigen
-
Humans
-
Mycosis Fungoides* / drug therapy
-
Skin Neoplasms* / drug therapy
Substances
-
Antibodies, Monoclonal, Humanized
-
B7-H1 Antigen
-
CD274 protein, human
-
pembrolizumab